SCHEMBL23770862

SCHEMBL23770862

Cc1ccccc1-c1nc(NSc2cccc(N3CCNCC3)n2)ccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 2/20 0.42
HTR3B O95264 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HTR3A P46098 2/20 0.42
HTR3D Q70Z44 2/20 0.42
HTR3C Q8WXA8 2/20 0.42
CYP1A2 P05177 4/20 0.40
HTR7 P34969 4/20 0.39
HTR1A P08908 2/20 0.38
PTPN11 Q06124 1/20 0.37
CYP3A4 P08684 3/20 0.37
CYP2D6 P10635 2/20 0.37
TSHR P16473 2/20 0.37
CLK4 Q9HAZ1 1/20 0.37
CCNK O75909 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCND3 P30281 1/20 0.36
CDK9 P50750 1/20 0.36
CDK6 Q00534 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770450 0.90 HTR3E (0.43) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770808 0.88 HTR3E (0.38) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770731 0.88 HTR3A (0.40) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770663 0.86 CYP1A2 (0.43) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770819 0.85 HTR3A (0.41) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770661 0.83 HTR3A (0.39) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770669 0.83 HTR3A (0.40) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770475 0.81 L3MBTL1 (0.39) ALDH1A1MEN1KMT2AMAPK14KDM4E
SCHEMBL23770837 0.81 SMO (0.34) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL19925768 0.79 HTR3E (0.40) HTR3EHTR3BALDH1A1HTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed